Thomas U. Marron
YOU?
Author Swipe
View article: TREM2 macrophages are associated with enhanced response to PD-1 blockade in human hepatocellular carcinoma
TREM2 macrophages are associated with enhanced response to PD-1 blockade in human hepatocellular carcinoma Open
Macrophages are known to dampen tumor immunity. However, identifying druggable targets that modulate these cells to improve existing immunotherapies has been limited by a dearth of studies identifying macrophages that associate with pathol…
View article: Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline
Multiparametric cellular and spatial organization in cancer tissue lesions with a streamlined pipeline Open
Multiplex immunostaining analysis remains fragmented, underperforming and labour intensive despite tissue proteomic methodologies achieving ever-increasing marker complexity. Here we propose an open-source, user-guided automated pipeline t…
View article: Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma Open
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observe comparable overall survival across …
View article: Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma Open
Background Despite improved outcomes with atezolizumab plus bevacizumab (A+B) in hepatocellular carcinoma (HCC), primary refractoriness (PRef), characterised by early progression or short-lived disease stabilisation following treatment, re…
View article: Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma
Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma Open
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observed comparable overall survival across…
View article: Data from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Data from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Immunotherapies like immune checkpoint inhibitors (ICI) have changed the standard of care for patients with cancer, often leading to durable responses. However, many patients remain or become refractory to ICIs owing to factors such as a l…
View article: Supp Fig7+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig7+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig7. Characterizing peripheral cellular immune environment in patients receiving PGV001. Multicolor flowcytometry performed to phenotype circulating immune cells in patients and healthy donors (HD). PID-017 was excluded from…
View article: Supplementary Table3 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table3 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Table3: List of mutated peptide IDs and peptide sequence in each patients’ vaccine
View article: Supp Fig3 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig3 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig3. Neoantigen specific antibody responses induced by PGV001. Patient plasma was subjected to seromics by ELISA using linear SLPs in the vaccines. N=12 patients. PID-017 excluded from analysis due to high background. a) Sta…
View article: Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Table2 – Variant count per patient
View article: Supp Fig5+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig5+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig5. TCR sequencing on neoantigen reactive T cells in patient PBMCs a) (Top) Depiction of methodology utilized to generate ex vivo and in vitro expanded and stimulated (IVS) T cell samples from screen, week 8 (W8) and week 2…
View article: Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig1. PGV001 feasibility and recurrence free survival a) Survival plot depicting overall survival (OS). N=12. Median survival depicted by vertical dotted line b) Survival plot depicting recurrence free survival (RFS). Median …
View article: Supplementary Table5 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table5 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Table5: Cellular Immunophenotyping antibody panels
View article: Supplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Table1. Staging at time of enrollment, adjuvant treatment following curative intent treatment until the end of vaccination and vaccination timing
View article: Supp Fig6+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig6+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig6. Gating strategy for phenotyping of immune cells by flow cytomtery. EM: Effector memory, TEMRA: Effector memory Re-expression RA, CM: Central Memory
View article: Supp Fig4+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig4+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig4. CD4+ and CD8+ T cell activation by PGV001 PBMCs from patients were expanded in vitro in presence of neoantigen peptides (pools of peptides, OLPs+Mins, corresponding to each vaccine SLP) and restimulated with peptide/s f…
View article: Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Table4: Number of Subjects who had Treatment Emergent Adverse Events by grade, system (13 subjects)
View article: Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig2. PGV001-induced T cell immunity as measured by ex vivo IFNγ ELISPOT assay PBMC samples were stimulated with neoantigen peptides (pools of peptides: composed of 15mer OLPs+ 9-10mer predicted Mins corresponding to each vac…
View article: MARQO pipeline resolves multiparametric cellular and spatial organization in cancer tissue lesions
MARQO pipeline resolves multiparametric cellular and spatial organization in cancer tissue lesions Open
Multiplex immunostaining analysis remains fragmented, underperforming, and labor-intensive despite tissue proteomic methodologies achieving ever-increasing marker complexity. Here we propose an open-source, semi-supervised automated pipeli…
View article: ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab Open
A Higher ALBI grade was associated with an increased risk of gastrointestinal bleeding after receiving A+B, and outperformed the CP score in predicting worse survival.
View article: A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy Open
Clinical trials of cancer immunotherapy (IO) were historically based on a drug development paradigm built for chemotherapies. The remarkable clinical activity of programmed cell death protein 1/programmed death ligand 1 blockade, chimeric …
View article: Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer
Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer Open
Tertiary lymphoid structures (TLS) are organized immune cell aggregates that arise in chronic inflammatory conditions. In cancer, TLS are associated with better prognosis and enhanced response to immunotherapy, making these structures attr…
View article: Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials Open
PURPOSE Financial toxicity (FT) adversely influences patient quality of life and is a barrier to clinical trial enrollment. Early-phase clinical trials (EPCTs) recruit patients who may have high baseline FT and require additional visits an…